Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma ; volume:1 ; number:1 ; day:26 ; month:3 ; year:2012 ; pages:1-2 ; date:12.2012
Experimental hematology & oncology ; 1, Heft 1 (26.3.2012), 1-2, 12.2012
- Urheber
-
Wei, Guoqing
Nwakuche, Uzoma
Cadavid, Gustavo
Ajaz, Asim
Seiter, Karen
Liu, Delong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/2162-3619-1-3
- URN
-
urn:nbn:de:101:1-2021082019111449711006
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wei, Guoqing
- Nwakuche, Uzoma
- Cadavid, Gustavo
- Ajaz, Asim
- Seiter, Karen
- Liu, Delong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Acute visual loss after ipilimumab treatment for metastatic melanoma
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Acute visual loss after ipilimumab treatment for metastatic melanoma
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Acute visual loss after ipilimumab treatment for metastatic melanoma
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Ipilimumab in patients with melanoma and autoimmune disease
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma